Condition: Brain Tumor · Non Small Cell Lung Cancer · Sponsor: InSightec
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.
This description comes directly from the study's public registry record.
Alyssa Voelker-Christy · 817-948-5219 · clinicalresearchquestions@insightec.com
Always discuss trial participation with your own doctor first.
| St. Joseph's Hospital and Medical Center | Phoenix, Arizona, United States | Not Yet Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Miami Cancer Institute at Baptist Health | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Maryland | Baltimore, Maryland, United States | Recruiting |
| Atrium Health Wake Forest Baptist | Winston-Salem, North Carolina, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Rhode Island Hospital | Providence, Rhode Island, United States | Recruiting |
| Johnston Willis Hospital | Richmond, Virginia, United States | Recruiting |
| Sunnybrook Research Institute | Toronto, Ontario, Canada | Completed |
| Samsung Medical Center | Seoul, Seoul, South Korea | Not Yet Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Not Yet Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05317858